The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: Is there a gender effect?

Neurology

Volumn 69, Issue 16, 2007, Pages 1595-1602

  Orr Urtreger, A ^a,b   Shifrin, C ^a,b   Rozovski, U ^a   Rosner, S ^a   Bercovich, D ^a   Gurevich, T ^a,b   Yagev More, H ^a   Bar Shira, A ^a   Giladi, N ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HAPLOTYPE; HETEROZYGOTE; HUMAN; ISRAEL; JEW; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; ETHNOLOGY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENOTYPE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; RISK FACTOR; SEX DIFFERENCE; SEXUAL DEVELOPMENT;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HAPLOTYPES; HETEROZYGOTE; HUMANS; JEWS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS; SEX CHARACTERISTICS; SEX FACTORS;

EID: 35848939603     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000277637.33328.d8     Document Type: Article

References (34)

1. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005;62:353-357.
2. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol 2005;18:363-369.
3. Brice A. Genetics of Parkinson's disease: LRRK2 on the rise. Brain 2005;128:2760-2762.
4. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
5. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
6. Bosgraaf L, Van Haastert PJ. Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 2003;1643:5-10.
7. Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 2005;102:18676-18681.
8. Hernandez DG, Paisan-Ruiz C, McInerney-Leo A, et al. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 2005;57:453-456.
9. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005;365:410-412.
10. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005;365:412-415.
11. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-416.
12. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680.
13. Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-765.
14. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006;63:377-382.
15. Lesage S, Leutenegger AL, Ibanez P, et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 2005;77:330-332.
16. Goldwurm S, Di Fonzo A, Simons EJ, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 2005;42:e65.
17. Zabetian CP, Hutter CM, Yearout D, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 2006;79:752-758.
18. Lesage S, Ibanez P, Lohmann E, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005;58:784-787.
19. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006;354:422-423.
20. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425.
21. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006;67:1786-1791.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
23. Orr-Urtreger A, Bar-Shira A, Bercovich D, et al. RNA-SEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:474-479.
24. Mata IF, Kachergus JM, Taylor JP, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005;6:171-177.
25. Zhao LP, Li SS, Khalid N. A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies. Am J Hum Genet 2003;72:1231-1250.
26. Funayama M, Hasegawa K, Ohta E, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005;57:918-921.
27. Tomiyama H, Li Y, Funayama M, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 2006;21:1102-1108.
28. Zabetian CP, Samii A, Mosley AD, et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 2005;65:741-744.
29. Goodman RM, Motulsky AG, eds. Genetic diseases among Ashkenazi Jews. New York: Raven Press; 1979.
30. Whaley NR, Uitti RJ, Dickson DW, Farrer MJ, Wszolek ZK. Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. J Neural Transm Suppl 2006;221-229.
31. Gosal D, Ross OA, Toft M. Parkinson's disease: the genetics of a heterogeneous disorder. Eur J Neurol 2006;13:616-627.
32. Kay DM, Zabetian CP, Factor SA, et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 2006;21:519-523.
33. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004;75:637-639.
34. Kay DM, Bird TD, Zabetian CP, et al. Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. Genet Test 2006;10:221-227.